Inspire Medical Systems (NYSE:INSP) Upgraded to Strong-Buy at Freedom Capital

Freedom Capital upgraded shares of Inspire Medical Systems (NYSE:INSP) to a strong-buy rating in a research note issued to investors on Tuesday,Zacks.com reports.

INSP has been the topic of a number of other research reports. Mizuho reduced their price objective on Inspire Medical Systems from $70.00 to $55.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 5th. Stifel Nicolaus lowered their target price on Inspire Medical Systems from $70.00 to $65.00 and set a “buy” rating for the company in a research report on Tuesday, May 5th. Truist Financial cut their target price on shares of Inspire Medical Systems from $64.00 to $50.00 and set a “hold” rating for the company in a report on Tuesday, May 5th. Piper Sandler cut shares of Inspire Medical Systems from an “overweight” rating to a “neutral” rating and reduced their price target for the stock from $85.00 to $55.00 in a research report on Tuesday, May 5th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Inspire Medical Systems from $67.00 to $54.00 and set a “neutral” rating on the stock in a research note on Tuesday, May 5th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, thirteen have assigned a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $81.05.

Inspire Medical Systems Stock Up 3.3%

INSP opened at $46.95 on Tuesday. The company has a market capitalization of $1.35 billion, a PE ratio of 10.46, a price-to-earnings-growth ratio of 4.60 and a beta of 0.71. The firm has a 50-day simple moving average of $44.71 and a two-hundred day simple moving average of $62.53. Inspire Medical Systems has a 52 week low of $38.91 and a 52 week high of $147.03.

Inspire Medical Systems (NYSE:INSP) last issued its earnings results on Monday, May 4th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.38. The firm had revenue of $204.58 million for the quarter, compared to analysts’ expectations of $200.04 million. Inspire Medical Systems had a return on equity of 10.35% and a net margin of 14.33%.The business’s revenue was up 1.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.10 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. As a group, sell-side analysts expect that Inspire Medical Systems will post 0.93 earnings per share for the current year.

Institutional Investors Weigh In On Inspire Medical Systems

Large investors have recently bought and sold shares of the company. Wellington Management Group LLP purchased a new stake in shares of Inspire Medical Systems in the 4th quarter valued at $203,929,000. M&T Bank Corp acquired a new stake in shares of Inspire Medical Systems in the fourth quarter worth $85,871,000. Deerfield Management Company L.P. raised its holdings in shares of Inspire Medical Systems by 648.4% during the third quarter. Deerfield Management Company L.P. now owns 1,047,694 shares of the company’s stock worth $77,739,000 after purchasing an additional 907,694 shares during the last quarter. Morgan Stanley raised its holdings in shares of Inspire Medical Systems by 179.5% during the fourth quarter. Morgan Stanley now owns 1,259,762 shares of the company’s stock worth $116,188,000 after purchasing an additional 809,121 shares during the last quarter. Finally, Fuller & Thaler Asset Management Inc. acquired a new position in Inspire Medical Systems during the fourth quarter valued at $61,619,000. Hedge funds and other institutional investors own 94.91% of the company’s stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.